EirGenix Reports Three-Year High Revenue, Demonstrating Strong Growth Momentum from Its Dual-Engine Global Strategy
EirGenix, Inc. (TWSE: 6589), a Taiwan-based biopharmaceutical company specializing in biosimilar development and contract development and manufacturing organization (CDMO) services, reported revenue exceeding NT$270 million in October 2026, bringing cumulative revenue for the first ten months of the year to NT$1.38 billion, representing a 94.7% year-over-year increase. Both monthly and cumulative revenue reached nearly Three-Year High.
The strong performance was primarily driven by continued expansion of the company's CDMO business and revenue contributions from licensing agreements covering global and Japanese markets for its biosimilar products, EG12014 and EG1206A. These results highlight the growing momentum of EirGenix's dual-engine strategy, combining CDMO services with biosimilar development and commercialization.
Dr. Lee-Cheng Liu, the Founder, Chairman and President of EirGenix, stated, "Our revenue growth is not solely dependent on individual milestone payments. In accordance with the relevant contractual terms and progress toward performance obligations, revenue associated with development milestones is recognized progressively based on the percentage of completion, rather than being recorded entirely in a single month. As our products advance through regulatory submissions, approvals, and commercialization, we anticipate additional milestone-related revenue, followed by post-launch profit-sharing opportunities, establishing sustainable revenue streams across multiple years."
EG1206A Advances Global Regulatory and Commercialization Plans
EirGenix's biosimilar candidate EG1206A reached a significant regulatory milestone with the formally accepted of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in late October 2026.
The company also plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application to Health Canada by the end of 2026.
During the first half of 2027, EirGenix and its global commercialization partner, Sandoz, plan to pursue regulatory submissions across 26 countries. EirGenix also expects to complete its marketing authorization submission to the Taiwan Food and Drug Administration (TFDA) within the same period, further accelerating EG1206A's global market expansion.
Commercialization plans currently target a European launch in 2027, followed by a U.S. launch in 2028, subject to regulatory approvals and commercialization arrangements with its partners.
EirGenix anticipates that major licensing milestone payments could be realized during 2027–2028 as regulatory reviews and approvals progress. Following commercial launch, the company also expects to receive contractual profit-sharing payments at high double-digit percentage rates, along with potential sales-based incentives. These revenue streams are expected to support the transition from product development and licensing toward longer-term commercial returns.
Expanding Biosimilar Pipeline to Support Long-Term Growth
Beyond EG1206A, EirGenix continues to advance its biosimilar pipeline.
EG12184, a subcutaneous biosimilar candidate targeting the multiple myeloma treatment market, is planned to enter clinical trials in 2027. The program has already attracted strong licensing interest from major international and Japanese pharmaceutical companies.
Looking ahead, EirGenix aims to establish a sustainable biosimilar development and commercialization pipeline, targeting one additional biosimilar product ready for market entry every 12 to 18 months beginning in 2029.
This long-term strategy is designed to create a more consistent product commercialization cycle and strengthen the company's future growth potential.
CDMO Business Expansion Strengthens International Market Presence
In parallel with its biosimilar development programs, EirGenix continues to expand its global CDMO partnerships and integrated, end-to-end biologics development and manufacturing services.
The company expects its CDMO business to maintain growth momentum throughout 2027 and 2028, supported by increasing international collaborations and demand for biologics manufacturing capabilities.
EirGenix's second manufacturing facility in Zhubei is currently preparing for an on-site inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The company is targeting the commencement of commercial product shipments for a Japanese customer in 2027, marking another important step in strengthening its presence in the Japanese biopharmaceutical market.
Positioned for a New Phase of Sustainable Growth
Dr. Lee-Cheng Liu further noted that the combination of increasing biosimilar licensing revenue, sustained CDMO business expansion, and growing contributions from commercialized products is expected to drive a more significant improvement in EirGenix's operating scale and profitability beginning in the second half of 2027.
"EirGenix is entering a new phase of growth, transitioning from product development and international licensing toward global commercialization and recurring revenue generation," Dr. Liu emphasized. "With the continued progress of our dual-engine strategy, we remain confident in our long-term growth prospects and our ability to build sustainable profitability structure."